Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies (NASDAQ: CLGN) operates at the intersection of plant biotechnology and regenerative medicine, creating news flow that spans bioprinting research breakthroughs, clinical development milestones, and commercial partnership announcements. As a specialty biotechnology company producing recombinant human collagen from genetically engineered plants, CollPlant generates coverage distinct from traditional pharmaceutical or medical device companies.
News coverage for CollPlant typically includes research collaboration announcements with academic institutions and medical centers developing 3D bioprinting applications. The company's partnerships with organizations such as Mayo Clinic and Technion-Israel Institute of Technology produce updates on bioprinting advancements and preclinical study results. These announcements provide insight into the trajectory of tissue engineering applications using the company's rhCollagen technology.
Commercial developments form another significant news category, including distribution agreement expansions for the VergenixSTR product line across European and Asian markets. Patent grants and regulatory approvals for collagen-based formulations mark intellectual property milestones that affect the company's competitive position in the biomaterials sector.
As a dual-listed company on NASDAQ and the Tel Aviv Stock Exchange, CollPlant releases quarterly financial results and corporate updates that detail research progress, commercial traction, and capital position. These announcements help track the company's progress toward broader commercialization of its plant-derived collagen platform.
Bookmark this page to follow CollPlant's bioprinting research developments, tissue repair product expansions, and partnership announcements as the company advances its regenerative medicine technology.
Stratasys (SSYS) and CollPlant (CLGN) have announced a joint development and commercialization agreement to focus on bioprinting solutions for regenerative breast implants, targeting a
CollPlant Biotechnologies (Nasdaq: CLGN) reported its financial results for the full year 2022, revealing a significant net loss of $16.9 million or $1.53 per share, compared to a profit of $237,000 in 2021. Revenue plummeted to $299,000, a decrease of $15.3 million year-over-year, largely due to a prior $14 million upfront payment from AbbVie. Despite these challenges, CollPlant is advancing its strategic collaboration with AbbVie in developing dermal fillers and is planning further studies for its 3D bioprinted breast implants, targeting a $2.6 billion market. The company ended 2022 with $29.7 million in cash and equivalents.
FAQ
What is the current stock price of Collplant Biotechnologies (CLGN)?
What is the market cap of Collplant Biotechnologies (CLGN)?
